Empresas suíças - Swisscam

Geistlich Biomaterials
Empresas suíças no CIOC | 29 de janeiro a 01 de fevereiro de 2011 | São Paulo | Brasil
Swiss companies at CIOC | January 29 to February 1, 2011 | Sao Paulo | Brazil
Leading regeneration.
No CIOSP 2010, a Geistlich Pharma do
Brasil se apresentou pela primeira vez –
a equipe brasileira com os colegas
da Suíça e de Portugal.
In CIOSP 2010, Geistlich Pharma do
Brasil performed for the first time –
the Brazilian team with the colleagues
from Switzerland and Portugal.
RESEARCH AND DEvELOPMENT
TO ENHANCE quALITy OF LIFE
Geistlich Pharma AG specializes
in regenerative medicine, and its
“Geistlich Biomaterials” unit is a world
leader in regenerative dentistry. Here,
the scientific character is essential.
Its scientific character is solidly anchored
in the company philosophy and product
development – ever since it was founded.
Therefore, the actual research and
development – compared to the number of
employees – are extraordinarily large. In the
1980s, Dr. Peter Geistlich, executive president
of Geistlich Pharma AG, decided to invest
in biomaterials for regenerative medicine.
Together with international researchers,
Dr. Peter Geistlich managed pioneering
research and developed a bone substitution
material called Geistlich Bio-Oss ® and
a collagen membrane for bone regeneration
called Geistlich Bio-Gide ® .
Never change a winning team
Geistlich Pharma AG specialized in
regenerative medicine. With this expertise
the company now operates in the
soft-tissue management segment. In this
activity, the company remains committed
to research and development based on
science, for both existing and new products.
until now over 700 studies have been
conducted. For Geistlich Pharma AG, it is
important to know what experts really need
for their patients, and, for this purpose, we
rely on a worldwide network of scientists
and clinicians to jointly develop new
products and suggestions. The company
is committed to cooperation ventures and
continually invests in new research.
Focus: science for the benefit of patients
Since August 2010, Dr. Terance Hart has been
a member of the board as the new Chief
Scientific Officer (CSO). Dr. Hart defines
his vision of science as follows: “We must
learn how cells communicate and interact.
Our products must be easy to use for doctors,
and they must be able to use these products
to securely predict treatment outcomes.
We continue focusing our science on unmet
needs of our clients and their patients.”